The list of shame no biopharma wants to join
An upcoming Icer report will put the spotlight on unjustified price increases even as signs of moderation emerge.
In sticking to the knitting has Array given up too much?
At a time when most of biotech seems to want to become “the next Genentech” Array Biopharma has stuck to a partnering model and, in hindsight, lost out in the process.
Gene therapy: how much will it cost patients?
Bluebird Bio has pushed forward the conversation on how to make million-dollar treatments affordable for insurers, but biopharma and payers are ominously quiet about…
Round two for Axsome
Fresh from a mid-stage success in depression Axsome offers an unusual way to trade its upcoming phase III result.
Smaller groups await Bristol-Myers Squelgene fallout
Celgene had many fingers in many pies – so what will happen now to its smaller collaborators?
Big pharma consolidation: the tectonic plates shift
The takeover of Celgene has disrupted pharma’s conventional wisdom on which companies should merge and when. This is how things now stand.
Why Novo Nordisk should buy Amarin
Pfizer is said to be interested in Amarin, but the Danish group’s need for a growth injection is greater.
Tiny populations up the ante for gene therapy pricing
Digging into the sales forecasts for gene therapies shows just how low their penetration is expected to be. Could biopharma come to regret its high-price, low-volume…
Biopharma in 2019 – navigating choppy waters
Vantage publishes its annual look ahead to 2019, examining the trends and issues that will shape biopharma in the coming year.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.